Mycophenolate Mofetil in Membranous Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00135967|
Recruitment Status : Completed
First Posted : August 26, 2005
Last Update Posted : December 6, 2005
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects.
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.
|Condition or disease||Intervention/treatment||Phase|
|Glomerulonephritis, Membranous||Drug: mycophenolate mofetil orally 1000 mg twice a day (BID) Drug: prednisone 0,5 mg/kg orally on alternate days Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study|
|Study Start Date :||May 2002|
- renal function (serum creatinine)
- side effects
- relapse rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00135967
|Department of Nephrology Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500 HB|
|Principal Investigator:||Jack F Wetzels, MD||Radboud University|